retatrutide nonalcoholic steatohepatitis trial Results: 28.3% Weight Loss Data Combination therapy for non-alcoholic steatohepatitis:

The placebo group had merely a 2% average weight loss

A waiver of consent was approved because of the retrospective nature of the study with a large number of patients and due to the research involving no more than minimal risk (including privacy risks) to the individuals

This likely reflects dose differences rather than efficacy differences, but it definitively disproves the myth that diabetes is required for weight loss response

The GLP-1 receptor agonist liraglutide reverses mania-like alterations and memory deficits induced by d-amphetamine and augments lithium effects in mice: relevance for bipolar disorder